ORTEXORTEX News
Tracking SKT? Get live short interest, options flow, and signals on ORTEX.Sign up free →
SK
Earnings PreviewSKT

Tanger Heads Into Q2 Print With Short Interest at a One-Month High

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 5 Aug 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

SKT reports second-quarter results on August 5 against a backdrop of rising short positioning and a stock that has pulled back 3.3% on the week — setting up a direct test of whether the outlet REIT's fundamentals can match the momentum that drove a 22% year-to-date gain.

Short interest has climbed meaningfully into the print. Shorts represent 5.2% of the free float, up 30% over the past month to sit at the highest level in the 30-day window. Monday's session saw a sharp single-day drop of 13%, but the underlying trend through July has been steadily higher — from roughly 4.6 million shares shorted in early July to above 6 million. That said, the borrow market is not under any stress. Availability runs at over 950% of outstanding short interest, meaning there are roughly nine shares available to borrow for every one already lent out. Cost to borrow is just 0.35% and has fallen 26% over the week, suggesting no squeeze dynamic and ample room for further short-selling if sentiment deteriorates.

Options traders have turned modestly more defensive ahead of the release. The put/call ratio is running at 0.16, well above its 20-day average of 0.12, with a z-score of 1.77 — the most protective skew in recent weeks, though still nowhere near extreme on an absolute basis. The stock slipped 0.07% on Tuesday and is down 3.3% over the past five sessions, underperforming close peers: KRG fell 5.0% on the week and KIM dropped 3.7%, so the sector tone has been broadly weak. SPG and MAC held up better, each down roughly 1%.

The analyst setup is split, but leans cautious. BofA downgraded SKT to Underperform in mid-June, holding its target at $38 — below the current price of $40.72. Deutsche Bank, Scotiabank, and Evercore ISI all maintained neutral-to-hold-equivalent ratings while lifting targets into the $39–$41 range over June and early July. BMO and Ladenburg Thalmann sit at Market Perform and Buy respectively, both with $42 targets. The consensus mean target of $40.73 is virtually flat to the current price, leaving the return potential near zero — a signal that the Street sees the stock as fairly valued after the year-to-date run. ORTEX factor scores add texture: EPS momentum over 30 days ranks in the 66th percentile, a reasonable read, but the short score rank of 20 and the DTC rank of 29 both reflect above-average short positioning relative to the broader universe.

Fidelity added over 3.3 million shares in the most recent filing period, making it the second-largest institutional holder at 13%. BlackRock holds 18%. The insider picture is less constructive — in March, the CEO, CFO, and COO all sold shares at $35.48 following a large equity award cycle, the typical post-vesting pattern for REIT management. Net 90-day insider value is positive only because the awards dwarf the open-market sales.

The print will test whether SKT's operating performance — occupancy trends, leasing spreads, and same-centre sales — justifies a stock trading at 35x earnings and 16.8x EV/EBITDA, particularly now that analyst consensus offers no further price appreciation and short sellers have been quietly adding exposure through July.

Stocks in this article

See the live data behind this article on ORTEX.

Open SKT on ORTEX →

How this article was generated

Generated
5 Aug 2026, 04:15
Data as of
5 Aug 2026, 04:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.